JP2013500940A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500940A5
JP2013500940A5 JP2012505915A JP2012505915A JP2013500940A5 JP 2013500940 A5 JP2013500940 A5 JP 2013500940A5 JP 2012505915 A JP2012505915 A JP 2012505915A JP 2012505915 A JP2012505915 A JP 2012505915A JP 2013500940 A5 JP2013500940 A5 JP 2013500940A5
Authority
JP
Japan
Prior art keywords
antibody
subject
sample
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500940A (ja
JP5599454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2010/004926 external-priority patent/WO2011016239A1/en
Publication of JP2013500940A publication Critical patent/JP2013500940A/ja
Publication of JP2013500940A5 publication Critical patent/JP2013500940A5/ja
Application granted granted Critical
Publication of JP5599454B2 publication Critical patent/JP5599454B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505915A 2009-08-06 2010-08-05 Ａβオリゴマーに特異的に結合する抗体およびその利用 Expired - Fee Related JP5599454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23179709P 2009-08-06 2009-08-06
US61/231,797 2009-08-06
US28255010P 2010-02-26 2010-02-26
US61/282,550 2010-02-26
PCT/JP2010/004926 WO2011016239A1 (en) 2009-08-06 2010-08-05 Antibodies that specifically bind to a beta oligomers and use thereof

Publications (3)

Publication Number Publication Date
JP2013500940A JP2013500940A (ja) 2013-01-10
JP2013500940A5 true JP2013500940A5 (enExample) 2014-05-15
JP5599454B2 JP5599454B2 (ja) 2014-10-01

Family

ID=43544148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505915A Expired - Fee Related JP5599454B2 (ja) 2009-08-06 2010-08-05 Ａβオリゴマーに特異的に結合する抗体およびその利用

Country Status (7)

Country Link
US (1) US8613924B2 (enExample)
EP (1) EP2462162B1 (enExample)
JP (1) JP5599454B2 (enExample)
CN (1) CN102596997B (enExample)
DK (1) DK2462162T3 (enExample)
ES (1) ES2614949T3 (enExample)
WO (1) WO2011016239A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CN102936287B (zh) 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
CN108020673A (zh) * 2017-11-15 2018-05-11 首都医科大学宣武医院 Aβ试剂盒、检测方法及应用
SG11202007055QA (en) * 2018-03-08 2020-09-29 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
SG11202008098TA (en) * 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN111662381B (zh) * 2019-03-07 2022-06-07 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
US20230034474A1 (en) * 2019-09-10 2023-02-02 Ac Immune Sa Novel Molecules for Diagnosis
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
JP7634082B2 (ja) * 2020-08-18 2025-02-20 オメロス コーポレーション 補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
CN114573694B (zh) * 2020-12-01 2023-09-01 深圳华柏生物科技有限公司 一种抗IL13Rα2抗体及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
DE60226036T9 (de) 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
EP1769002A1 (en) * 2004-07-02 2007-04-04 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
PT1830881E (pt) * 2004-12-10 2010-08-30 Novimmune Sa Terapias de combinação visando múltiplos receptores do tipo toll e a sua utilização
CA2589017A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006094724A2 (en) * 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
WO2006137354A1 (ja) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
EP1749839A1 (en) 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
CN102936287B (zh) 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof

Similar Documents

Publication Publication Date Title
JP2013500940A5 (enExample)
JP2013500941A5 (enExample)
JP7399096B2 (ja) 神経変性を検出するためのアッセイ
KR101981351B1 (ko) 타우를 인식하는 포스포특이적 항체
KR101988672B1 (ko) 타우를 인식하는 포스포특이적 항체
JP7837375B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
RU2743152C2 (ru) Гуманизированные анти-тау-антитела
JP2015530971A5 (enExample)
FI2897981T3 (fi) Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä
JP2015531768A5 (enExample)
RU2016141561A (ru) Связывающие элементы к фно-альфа
JP2014530597A5 (enExample)
JP2016503293A5 (enExample)
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
JP2014533357A5 (enExample)
JP2025530718A (ja) 抗タウｍｔｂｒ抗体、ならびにタウの切断された断片の検出方法およびその用途
JP2024001208A (ja) 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
WO2017079835A1 (en) Amyloid beta epitopes and antibodies thereto
WO2012021475A2 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
JP2018525320A5 (enExample)
WO2012149334A2 (en) Methods and compositions for the generation and use of conformation-specific antibodies
Dornieden et al. Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: a biotechnical tool for studies on Alzheimer’s disease?
TW202346865A (zh) 檢定
JP2026509486A (ja) 神経変性障害を診断および処置する方法
JP2026503664A (ja) 抗ａベータ抗体を用いた神経障害の治療方法